DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Trans...( PRINCETON N.J. June 29 /- Amo...)

PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning in Bone Marrow Transplantation in which they demonstrate that DOR's lead product orBec(R) (oral beclomethasone dipropionate or BDP) decreases non-infectious inflammation of the lung in acute gastrointestinal Graft-versus-Host disease (GI GVHD) patients who received allogeneic hematopoietic cell transplants (HCT). Non-infectious inflammation of the lung is a common and potentially fatal complication of HCT that decreases the exchange of oxygen and carbon dioxide between the lung and blood and, in its severe form, may present as interstitial pneumonitis. The full article, entitled "Influence of Oral Beclomethasone Dipropionate on Early Non-Infectious Pulmonary Outcomes after Allogeneic Hematopoietic Cell Transplantation: Results from Two Randomized Trials," is available online at: http://www.nature.com/bmt/journal/vaop/ncurrent/abs/bmt2009129a.html.

Among the data published:

1. A decrease in gas exchange as measured by the diffusion of carbon monoxide from the lung (DLCO) was observed in 33 of 42 (79%) of the placebo-treated patients, from pre-transplant to 80 days after randomization, as compared to 27 of 49 (55%) of the orBec(R)-treated patients (p = 0.02).
2. In the first 200 days after randomization, four of the patients treated with placebo developed non-infectious pulmonary complications, such as idiopathic pneumonia syndrome and c
   '/>"/>